Cubist Pharmaceuticals, Incorporated

Dsm Nutritional Products Inc.

Biosource Pharm, Inc.

Eli Lilly and Company

Merck Sharp + Dohme Corp.

Kaleido Biosciences, Inc.

Dsm IP Assets B.v.

Christopher Matthew Liu

Blaise S Lippa

John M Geremia

William V Curran

Richard A Leese

Iwona Wrona

Qingyi Li

You Seok Hwang

Yanzhi Zhang

Amy C D Bombardier

Anastasia Lioubomirov

Andrew J Jackson

Bertrand Leo Chenard

Chester A Metcalf, Iii

Xinyuan Edward Wu

Richard A Earl

Matthew Frank Baevsky

Jared Peters Smit

Molly Krisann Gibson

Anastasia V Lioubomirov

Brett A Cowans

Lily Cheng

Max Hecht

Mitchell Antalek

Jonathan Lawrence

Tatyana Yatsunenko

Brian Meehan

Guohua Liang

Lisa Mcqueen

Lauren M Chapman

Chester A Iii Metcalf

Brett Cowans

Geoffrey A Von Maltzahn

Ulrich HÖLLER

Rudiger Hainz

Mitchell Tyler Antalek

Madeline Hartman

Maxwell B Hecht

Lisa Ann Laprade

Ghislain Schyns

Manuela Baur

Estel Canet-Martinez

Ian Tamburini

Richard Alan Earl

Han Yuan

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of hyperammonemia-related diseases (e.g., urea cycle disorders and hepatic encephalopathy).

Oligosaccharide compositions and methods of use thereof for reducing ammonia levels

Preparations of glycan polymers and variations thereof, pharmaceutical compositions, medical foods, supplements, foods, food ingredients, feed ingredients, and feed additives thereof, optionally comprising micronutrients, polyphenols, prebiotics, probiotics, or other agents are provided and methods of making same.

Methods of producing glycan polymers

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for reducing ammonia levels and for the treatment of related diseases.

Oligosaccharide compositions and methods of use thereof

The present invention relates to compounds of the Formula (I), or a pharmaceutically acceptable salt, pharmaceutical preparation, or pharmaceutical composition thereof, and their use for the treatment of pain, inflammatory disease, neuropathy, dermatological disorders, pulmonary conditions, and cough, as well as inhibiting the Transient Receptor Potential A1 ion channel (TRPA1).

Inhibiting the transient receptor potential A1 ion channel

This disclosure describes novel compounds and pharmaceutical compositions for inhibiting the TRPA1 ion channel and/or medical conditions related to TRPA1, such as pain and respiratory conditions.

Provided herein are novel compounds and novel protected compounds that can be derived from polymyxin, including, e.g., polymyxin A. The novel compounds have antibacterial properties against a diverse range of Gram negative bacteria and reduced toxicity compared to polymyxins such as polymyxin A. Also provided are antibacterial pharmaceutical compositions containing the novel compounds and novel protected compounds, as well as methods for preparing the antibacterial compounds and protected compounds.

Antibiotic compositions for the treatment of gram negative infections

Growing community of inventors

Somerville, MA, United States of America

Christopher Matthew Liu